• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

对《致编辑的信：关于“13价肺炎球菌结合疫苗（PCV13）与低剂量替代疫苗在菲律宾婴儿中的成本效益”》的回应

A Response to: Letter to the Editor Regarding "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".

作者信息

Perdrizet Johnna, Horn Emily K, Nua Winniefer, Perez-Peralta Judith, Nailes Jennifer, Santos Jaime, Ong-Lim Anna

机构信息

Global Health Economics and Outcomes Research, Pfizer Inc., 235 42nd Street, New York, NY, 10017, USA.

Pfizer Inc., Makati City, Philippines.

出版信息

Infect Dis Ther. 2022 Jun;11(3):1301-1303. doi: 10.1007/s40121-022-00639-3. Epub 2022 Apr 26.

DOI:10.1007/s40121-022-00639-3
PMID:35474191
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9124259/
Abstract

This communication seeks to address the questions of Dhere and colleagues in their letter on our study "Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) versus lower-valent alternatives in Filipino infants." We hope to provide clarity on each of the three potential misunderstandings of our cost-effectiveness analysis that were raised by Dhere and colleagues.

摘要

本通讯旨在回应德雷及其同事在关于我们的研究《13价肺炎球菌结合疫苗（PCV13）与低剂量替代疫苗在菲律宾婴儿中的成本效益比较》的信件中提出的问题。我们希望就德雷及其同事提出的对我们成本效益分析的三个潜在误解逐一进行澄清。

相似文献

1
A Response to: Letter to the Editor Regarding "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".对《致编辑的信：关于“13价肺炎球菌结合疫苗（PCV13）与低剂量替代疫苗在菲律宾婴儿中的成本效益”》的回应
Infect Dis Ther. 2022 Jun;11(3):1301-1303. doi: 10.1007/s40121-022-00639-3. Epub 2022 Apr 26.
2
Response to Gomez et al.'s Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".对戈麦斯等人就《13价肺炎球菌结合疫苗（PCV13）与低价替代疫苗在菲律宾婴儿中的成本效益》致编辑信的回复。
Infect Dis Ther. 2022 Aug;11(4):1763-1765. doi: 10.1007/s40121-022-00641-9. Epub 2022 May 16.
3
Letter to the Editor Regarding: "Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants".致编辑的信：关于“13价肺炎球菌结合疫苗（PCV13）与低价位替代疫苗在菲律宾婴儿中的成本效益比较”
Infect Dis Ther. 2022 Aug;11(4):1757-1761. doi: 10.1007/s40121-022-00640-w. Epub 2022 May 16.
4
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants.13价肺炎球菌结合疫苗（PCV13）与低价替代疫苗在菲律宾婴儿中的成本效益比较
Infect Dis Ther. 2021 Dec;10(4):2625-2642. doi: 10.1007/s40121-021-00538-z. Epub 2021 Sep 30.
5
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants.13价肺炎球菌结合疫苗（PCV13）与低价替代疫苗在菲律宾婴儿中的成本效益分析
Infect Dis Ther. 2022 Jun;11(3):1297-1299. doi: 10.1007/s40121-022-00643-7. Epub 2022 Apr 28.
6
Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea.在韩国，13价肺炎球菌结合疫苗与10价肺炎球菌结合疫苗的国家免疫规划的成本效益比较。
Hum Vaccin Immunother. 2021 Mar 4;17(3):909-918. doi: 10.1080/21645515.2020.1796426. Epub 2020 Aug 12.
7
Reply letter to "response to article by Johnna Perdrizet et al." by Gomez and colleagues.致 Gomez 等人对 Johnna Perdrizet 等人文章的回应的回复信。
Hum Vaccin Immunother. 2022 Dec 31;18(1):1917237. doi: 10.1080/21645515.2021.1917237. Epub 2021 Apr 28.
8
Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.西班牙健康婴儿和幼儿中 13 价肺炎球菌结合疫苗和同时接种的脑膜炎球菌 C 群结合疫苗的评估。
Vaccine. 2013 Nov 4;31(46):5486-94. doi: 10.1016/j.vaccine.2013.06.049. Epub 2013 Sep 1.
9
Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.免疫功能低下成人患者中，接种 13 价肺炎球菌结合疫苗替代 23 价肺炎球菌多糖疫苗的成本效益分析。
Vaccine. 2013 Dec 5;31(50):6011-21. doi: 10.1016/j.vaccine.2013.10.024. Epub 2013 Oct 19.
10
Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.加拿大 13 价和 10 价肺炎球菌结合疫苗 2+1 剂量接种的成本效益。
BMC Infect Dis. 2012 Apr 24;12:101. doi: 10.1186/1471-2334-12-101.

本文引用的文献

1
Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation.婴幼儿对肺炎球菌结合疫苗的免疫反应与疫苗实施后的间接保护之间的关系。
Expert Rev Vaccines. 2019 Jun;18(6):641-661. doi: 10.1080/14760584.2019.1627207. Epub 2019 Jun 22.
2
Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report.疫苗接种项目的经济学分析：ISPOR 成果研究实践良好报告。
Value Health. 2018 Oct;21(10):1133-1149. doi: 10.1016/j.jval.2018.08.005.